Pharmaceutical Grade 95% Dihydroquercetin Taxifolin

Dihydroquercetin is not mutagenic and less toxic than the related compound quercetin. It acts as a potentialchemopreventive agent by regulating genes via an ARE-dependent mechanism. Taxifolin has shown to inhibit theovarian cancer cell growth in a dose-dependent manner. There is also a strong correlation (with a correlation coefficient of 0.93) between the antiproliferative effects of dihydroquercetin (DHQ, Dihydroquercetin) derivatives on murine skin fibroblasts and human breast cancer cells.

The capacity of Dihydroquercetin to stimulate fibril formation and promote stabilization of fibrillar forms of collagencan be used in medicine. Also taxifolin inhibited the cellular melanogenesis as effectively as arbutin, one of the most widely used hypopigmenting agents in cosmetics. However, arbutin acts as quercetin extremely mutagenic,carcinogenic and toxic.

Dihydroquercetin enhanced also the efficacy of conventional antibiotics and ceftazidime in vitro, which have potential for combinatory therapy of patients infected with methicillin-resistant Staphylococcus aureus(MRSA).

Dihydroquercetin, as well as many other flavonoids, has been found to act as a non-selective antagonist of the opioid receptors, albeit with somewhat weak affinity.

1. Dihydroquercetin can improving blood capillary elastic, anti-inflammatory.
2. Dihydroquercetin can antioxidation especially prostatic cancer.
3. Dihydroquercetin can preventing vascular disease.
4. Dihydroquercetin can maintaining vascular resistance.